Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Ceconi

Showing results (51-60 of 74) with videos related to

Pageof 8
Sort By:
Circulation|February 9, 2005
Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) studyMarco Valgimigli, Claudio Ceconi, Patrizia Malagutti, et al.
Trials|February 20, 2016
The combined effect of subcutaneous granulocyte- colony stimulating factor and myocardial contrast echocardiography with intravenous infusion of sulfur hexafluoride on post-infarction left ventricular function, the RIGENERA 2.0 trial: study protocol for a randomized controlled trialAntonio Maria Leone, Domenico D'Amario, Luciana Teofili, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 11, 2023
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022Juan Tamargo, Stefan Agewall, Claudio Borghi, et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|December 2, 2011
[Preventive cardiology: comparisons of European and Italian projects with the Cardiac Units from Emilia Romagna region. A workshop of IACPR/GICR - Emilia Romagna]Massimo F Piepoli, Antonio Brambilla, Lorenzo Brambilla, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 13, 2018
Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a reviewAlexander Vonbank, Heinz Drexel, Stefan Agewall, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 21, 2024
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023Juan Tamargo, Stefan Agewall, Claudio Borghi, et al.
European Heart Journal|January 13, 2017
Comprehensive efforts to increase adherence to statin therapyAlexander Vonbank, Stefan Agewall, Keld Per Kjeldsen, et al.
European Heart Journal|November 11, 2017
Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyAlexander Niessner, Juan Tamargo, Lorenz Koller, et al.
European Heart Journal|September 22, 2022
Sex differences in arterial hypertensionEva Gerdts, Isabella Sudano, Sofie Brouwers, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 29, 2022
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyJuan Tamargo, Keld Per Kjeldsen, Eva Delpón, et al.
Pageof 8

Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
Circulation|February 9, 2005
Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) studyMarco Valgimigli, Claudio Ceconi, Patrizia Malagutti, et al.
Trials|February 20, 2016
The combined effect of subcutaneous granulocyte- colony stimulating factor and myocardial contrast echocardiography with intravenous infusion of sulfur hexafluoride on post-infarction left ventricular function, the RIGENERA 2.0 trial: study protocol for a randomized controlled trialAntonio Maria Leone, Domenico D'Amario, Luciana Teofili, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 11, 2023
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022Juan Tamargo, Stefan Agewall, Claudio Borghi, et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|December 2, 2011
[Preventive cardiology: comparisons of European and Italian projects with the Cardiac Units from Emilia Romagna region. A workshop of IACPR/GICR - Emilia Romagna]Massimo F Piepoli, Antonio Brambilla, Lorenzo Brambilla, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 13, 2018
Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a reviewAlexander Vonbank, Heinz Drexel, Stefan Agewall, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 21, 2024
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023Juan Tamargo, Stefan Agewall, Claudio Borghi, et al.
European Heart Journal|January 13, 2017
Comprehensive efforts to increase adherence to statin therapyAlexander Vonbank, Stefan Agewall, Keld Per Kjeldsen, et al.
European Heart Journal|November 11, 2017
Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyAlexander Niessner, Juan Tamargo, Lorenz Koller, et al.
European Heart Journal|September 22, 2022
Sex differences in arterial hypertensionEva Gerdts, Isabella Sudano, Sofie Brouwers, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 29, 2022
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyJuan Tamargo, Keld Per Kjeldsen, Eva Delpón, et al.
Pageof 8